150 related articles for article (PubMed ID: 35246827)
1. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE).
Hata A; Shiraishi Y; Inui N; Okada M; Morise M; Akiyoshi K; Takeda M; Watanabe Y; Sugawara S; Shinagawa N; Kubota K; Saeki T; Tamura T
Oncol Ther; 2022 Jun; 10(1):253-262. PubMed ID: 35246827
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE.
Hata A; Okamoto I; Inui N; Okada M; Morise M; Akiyoshi K; Takeda M; Watanabe Y; Sugawara S; Shinagawa N; Kubota K; Saeki T; Tamura T
J Clin Oncol; 2022 Jan; 40(2):180-188. PubMed ID: 34793245
[TBL] [Abstract][Full Text] [Related]
3. A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC).
Zhang L; Lu S; Feng J; Dechaphunkul A; Chang J; Wang D; Chessari S; Lanzarotti C; Jordan K; Aapro M
Ann Oncol; 2018 Feb; 29(2):452-458. PubMed ID: 29092012
[TBL] [Abstract][Full Text] [Related]
4. Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for Cisplatin-Induced Nausea and Vomiting During the Extended Overall Phase.
Inui N; Toi Y; Yoneshima Y; Morise M; Hata A; Kubota K; Saeki T; Tamura T
Adv Ther; 2023 Nov; 40(11):4928-4944. PubMed ID: 37715851
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3-day aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study.
Chang J; Chen G; Wang D; Wang G; Lu S; Feng J; Li W; Li P; Lanzarotti C; Chessari S; Zhang L
Cancer Med; 2020 Jul; 9(14):5134-5142. PubMed ID: 32472742
[TBL] [Abstract][Full Text] [Related]
6. A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy.
Zelek L; Debourdeau P; Bourgeois H; Wagner JP; Brocard F; Lefeuvre-Plesse C; Chauffert B; Leheurteur M; Bachet JB; Simon H; Mayeur D; Scotté F
Oncologist; 2021 Oct; 26(10):e1870-e1879. PubMed ID: 34216177
[TBL] [Abstract][Full Text] [Related]
7. Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial.
Zhang Z; Yang Y; Lu P; Li X; Chang J; Zheng R; Zhou L; Chen S; Chen X; Ren B; Gu W; Jiang X; Peng J; Huang M; Feng G; Shen P; Zhang Q; Zhang B; Huang Y; He J; Chen Y; Cao J; Wang H; Li W; Wan H; Nan K; Liao Z; Zhang C; Lin Z; Zhong D; Xu Q; Liu H; Sun T; Deng Y; Zhang L
Ann Transl Med; 2020 Mar; 8(5):234. PubMed ID: 32309381
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of clinical outcomes and efficacy of palonosetron and granisetron in combination with dexamethasone in Egyptian patients receiving highly emetogenic chemotherapy.
A Mahrous M; A El-Azab G; A Tawfik H
Cancer Chemother Pharmacol; 2021 Jul; 88(1):121-129. PubMed ID: 33835230
[TBL] [Abstract][Full Text] [Related]
9. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy regimens: a subgroup analysis from a randomized clinical trial of response in subjects by cancer type.
Weinstein C; Jordan K; Green S; Khanani S; Beckford-Brathwaite E; Vallejos W; Pong A; Noga SJ; Rapoport BL
BMC Cancer; 2020 Sep; 20(1):918. PubMed ID: 32988373
[TBL] [Abstract][Full Text] [Related]
10. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
11. Comparison of oral aprepitant and intravenous fosaprepitant for prevention of chemotherapy-induced nausea and vomiting in pediatric oncology patients: a randomized phase III trial.
Yu LT; Wang Z; Han YL; Zhou F; Wagner LM; Zhang SG; Li ZL; Gao YJ
Transl Pediatr; 2024 Jan; 13(1):110-118. PubMed ID: 38323173
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial.
Weinstein C; Jordan K; Green SA; Camacho E; Khanani S; Beckford-Brathwaite E; Pong A; Noga SJ; Rapoport BL
Support Care Cancer; 2018 Nov; 26(11):3773-3780. PubMed ID: 29808377
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy - results of a non-interventional observation study.
Willier S; Cabanillas Stanchi KM; von Have M; Binder V; Blaeschke F; Feucht J; Feuchtinger T; Döring M
BMC Cancer; 2019 Nov; 19(1):1118. PubMed ID: 31730451
[TBL] [Abstract][Full Text] [Related]
14. Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Sugawara S; Inui N; Kanehara M; Morise M; Yoshimori K; Kumagai T; Fukui T; Minato K; Iwashima A; Takeda Y; Kubota K; Saeki T; Tamura T
Cancer; 2019 Nov; 125(22):4076-4083. PubMed ID: 31381152
[TBL] [Abstract][Full Text] [Related]
15. Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting.
Shirley M
Drugs; 2021 Jul; 81(11):1331-1342. PubMed ID: 34292534
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
17. Phase 3 Study of Palonosetron IV Infusion Vs. IV Bolus for Chemotherapy-Induced Nausea and Vomiting Prophylaxis After Highly Emetogenic Chemotherapy.
Karthaus M; Voisin D; Rizzi G; Ciuleanu T
J Pain Symptom Manage; 2020 Sep; 60(3):568-576. PubMed ID: 32276098
[TBL] [Abstract][Full Text] [Related]
18. Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy.
Gao A; Guan S; Sun Y; Wang L; Meng F; Liu X; Gu L; Li G; Zhong D; Zhang L
BMC Cancer; 2023 Jul; 23(1):609. PubMed ID: 37393241
[TBL] [Abstract][Full Text] [Related]
19. Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting.
Celio L; Ricchini F; De Braud F
Patient Prefer Adherence; 2013; 7():391-400. PubMed ID: 23687442
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
